Health Care Equipment

Nuwellis

Maxim Group Analyst Maintains Hold Rating on Nuwellis

Nuwellis released FY2025 9 Months Earnings on November 12 Pre-Market EST with actual revenue of USD 5.846 M and EPS of USD -89.3506

Nuwellis released FY2025 Q3 earnings on November 12 Pre-Market (EST), actual revenue USD 2.217 M (forecast USD 2.5 M), actual EPS USD 0.5607 (forecast USD -17.22)

Nuwellis to Release FY2025 Q3 Earnings on November 12, Pre-Market EST; Forecast Revenue USD 2.5 M, EPS USD -17.22

Nuwellis released FY2025 Semi-Annual earnings on August 14 During-Market EST, actual revenue USD 3.629 M, actual EPS USD -100.4251

Nuwellis released FY2025 Q2 earnings during market hours on August 14 (EST), actual revenue USD 1.725 M (forecast USD 2.2 M), actual EPS USD -60.9796 (forecast USD -18.9)

Nuwellis Plans to Cease International Operations

Nuwellis to release FY2025 Q2 earnings report on August 12 During-Market EST, forecast revenue USD 2.2 M, EPS USD -18.9

Nuwellis Inc Terminates Reverse HF Clinical Trial

Nuwellis Gains Fluid Management Patent, Stock Soars 61%

Nuwellis Completes $5 Million Underwritten Public Offering

Nuwellis, Inc. Announces Public Offering of Shares and Warrants

Nuwellis released FY2025 Q1 earnings during market hours on May 13 (EST), actual revenue USD 1.904 M (forecast USD 2.5 M), actual EPS USD -28.9316 (forecast USD -18.9)

Nuwellis reports Q1 2025 financial results

Nuwellis signs contract with KDI to strengthen production

Nuwellis to release FY2025 Q1 earnings report on May 13 During-Market EST, forecast revenue USD 2.5 M, EPS USD -0.45

Nuwellis released FY2024 Q4 earnings on March 11 During-Market EST: Actual Revenue USD 2.322M (Forecast USD 2.462M), Actual EPS USD -18.3076 (Forecast USD -18.06)

Nuwellis released FY2024 earnings on March 11 During-Market EST, actual revenue USD 8.74 M (forecast USD 8.88 M), actual EPS USD -336.19 (forecast USD -983.01)

Nuwellis Inc Reports Quarterly Financial Performance with Adjusted Loss of $0.70 per Share

Nuwellis Fourth Quarter Financial Performance Report

Intelligent Bio Solutions

Anghami

UTime

ESH ACQUISITION CORP COM USD0.0001 CL A (S/R 13/06/2028)

Northann

FG MERGER II CORP COM USD0.0001 11/02/2030 (SUBS/RTS)

ESH Acquisition

INFLECTION POINT ACQUISITION CORP V COM USD0.0001 CL A (SUB/RIGHST)

RISING DRAGON ACQUISITION CORP COM USD0.0001 15/11/2028 (SUBS/RT)

Datavault AI

Delcath

Electromed

Abbott Laboratories

Intuitive Surgical

Boston Scientific

Stryker

IDEXX Labs

Edwards Lifesciences

Resmed

DexCom

Style Score

Growth Score

Revenue YoY

Net Profit YoY

Value Score

P/B Ratio

Dividend Ratio

Size Score

Market Cap Score

Market Cap

Revenue Score

Revenue

Multi Score

Profit Score

Profit Margin

Gross Margin

Total Assets YoY

Net Assets YoY

Cash Score

Cash Flow Margin

OCF YoY

Operating Score

Turnover

Debt Score

Gearing Ratio

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap

Nuwellis(NUWE.US)